Huateng Pharmaceuticals Secures Investment from Shenghong Fund to Accelerate Development of Leading PEGylation and Microchannel Continuous Synthesis Platforms

VCBeat (WeChat ID: vcbeat) has learned at the earliest opportunity that, in recent days,Hunan Hua Teng Pharmaceutical Co., Ltd. (hereinafter referred to as “Hua Teng Pharmaceutical”) has newly introduced Shenghong Fund, with Kaicheng Capital serving as the exclusive financial advisor to the transaction parties.Hunan Hua Teng Pharmaceutical Co., Ltd., established in 2013, is an innovative high-tech enterprise providing products and technical services to global pharmaceutical and chemical manufacturers. It specializes in the development and industrialization of active pharmaceutical ingredients (APIs), long-acting targeted novel drugs, and high-end generic drugs. To date, leveraging its three core patented technology platforms—self-developed molecular fragment assembly technology, solid-phase synthesis technology, and gel filtration-ion exchange separation with super-macroporous media technology—the company has built the world’s largest library of PEGylating agents and successfully developed PEGylation technologies for multiple drugs. Furthermore, its internationally leading, independently owned continuous micro-flow reaction technology and pellet-based sustained-release formulation technology have been successfully applied in the development of various drug products, including the anti-influenza medications oseltamivir and baloxavir.

Hunan Hua Teng Pharmaceutical Co., Ltd. has achieved a breakthrough in resolving the longstanding challenges associated with PEGylating agents, namely the inability to determine drug molecular weight and batch-to-batch compositional heterogeneity, which have historically hindered FDA approval of PEGylated small-molecule drugs. With its internationally leading technology that fills a domestic gap, the company has become a supplier of this product series to numerous large pharmaceutical enterprises, providing them with high-quality products and comprehensive technical solutions.

“We are delighted by Shenghong Fund’s support and trust in Hua Teng. We are also proud that our rapid progress in product development logic, R&D timelines, and external collaborations has been recognized by numerous top-tier investors.”Dr. Deng Zeping, Chairman of Hua Teng Pharmaceuticalstated: “In the future, we will accelerate the development of our multiple projects and the construction of industrialization bases aligned with international standards, while further enhancing our proprietary PEG long-acting technology platform. This will enable us to develop blockbuster novel drugs with independent intellectual property rights. Leveraging the company’s inherent innovation DNA and strong execution capabilities, we will continue to promote the application of PEGylation technology in the development of therapeutics for other major diseases, thereby allowing more patients to benefit from long-acting formulations.”

Shenghong Fund, adhering to the development philosophy of “Professionalism First, Value Discovery,” integrates investment and research to focus on professional investments in niche segments of emerging industries such as healthcare, hard technology, and the new energy industrial chain. The core team members all come from top-tier domestic investment institutions, with an average of over 10 years of experience in equity investment, corporate management, and mergers and acquisitions. The cumulative amount invested and acquired exceeds RMB 10 billion. Representative projects include market leaders in their respective sectors, such as Huaren Pharmaceutical, Jiuyuan Yinhai, Guizhou Sanli, Xinhexin, Netease Technology (Nengte Tech), Fandi Biology, Zhongchao Medical, Sunpharm (Yangguang Nuohe), Olymvax, Vazyme, Piesi Gas, Houpu Shares, Chengda Biology, Xinte Energy, Zhongtian Energy, Giant Network, UCAR, Beike, Pinduoduo, and Luckin Coffee.

WinX Capital is a leading investment bank in China’s healthcare sector. Its founding team includes five Ph.D. holders in Global Finance from the PBC School of Finance at Tsinghua University, while its frontline professionals boast an average of over 10 years of experience in management, investment, and mergers and acquisitions (M&A), with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital maintains coverage of more than 3,000 active institutional investors and industrial groups. In 2020, it was ranked among the “Top 5 Most Promising New-Type Investment Banks in China” by 36Kr’s WISE 2020 list, and named one of the “Top 4 Best Financial Advisory Firms in Healthcare” for 2020 by Qiming Technology & Xinsheng Chuangfu.